title: Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands.
abstract: BACKGROUND
  Gefitinib, a tyrosine kinase inhibitor, is an effective treatment in advanced non-small cell lung cancer (NSCLC) patients with an activating mutation in the epidermal growth factor receptor (EGFR). Randomised clinical trials showed a benefit in progression free survival for gefitinib versus doublet chemotherapy regimens in patients with an activated EGFR mutation (EGFR M+). From a patient perspective, progression free survival is important, but so is health-related quality of life. Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. This study uses progression free survival rather than overall survival for its time frame in order to better compare the treatments and to account for the influence that subsequent treatment lines would have on overall survival analysis.
  
  
  METHODS
  Mean progression free survival for Pac/Carb was obtained by extrapolating the median progression free survival as reported in the Iressa-Pan-Asia Study (IPASS). Data from a network meta-analysis was used to estimate the mean progression free survival for therapies of interest relative to Pac/Carb. Adjustment for health-related quality of life was done by incorporating utilities for the Dutch population, obtained by converting FACT-L data (from IPASS) to utility values and multiplying these with the mean progression free survival for each treatment arm to determine the Quality Adjusted progression free survival. Probabilistic sensitivity analysis was carried out to determine 95% credibility intervals.
  
  
  RESULTS
  The Quality Adjusted progression free survival (PFS) (mean, (95% credibility interval)) was 5.2 months (4.5; 5.8) for Gem/Cis, 5.3 months (4.6; 6.1) for Pem/Cis; 4.9 months (4.4; 5.5) for Pac/Carb and 8.3 (7.0; 9.9) for gefitinib.
  
  
  CONCLUSIONS
  In the Dutch health care setting, the previously established progression free survival benefit of first-line gefitinib in advanced NSCLC EGFR M+ patients in comparison to standard doublet chemotherapy is further supported by the Quality Adjusted PFS, which takes into account the additional health-related quality of life benefits of gefitinib over doublet chemotherapy.
authors.affiliation: Mapi Consultancy, Houten, The Netherlands.
authors.forename: S Cora
authors.initials: SC
authors.lastname: Verduyn
authors.forename: Bonne
authors.initials: B
authors.lastname: Biesma
authors.forename: Franz M N H
authors.initials: FM
authors.lastname: Schramel
authors.forename: Feike W
authors.initials: FW
authors.lastname: van der Scheer
authors.forename: Merel K
authors.initials: MK
authors.lastname: Langenfeld
authors.forename: Maria A
authors.initials: MA
authors.lastname: de Peuter
authors.forename: Anne-Marie C
authors.initials: AM
authors.lastname: Dingemans
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000523:psychology*; D018572:Disease-Free Survival; D066246:ErbB Receptors; D005221:Fatigue / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D009154:Mutation; D009367:Neoplasm Staging; D009426:Netherlands; D011788:Quality of Life
chemical_list: C512478:EGFR protein, human; D066246:ErbB Receptors